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An important harmonization effort was produced by the scientific community to standardize both the preanalytical and
interpretative phases of programmed death-ligand 1 (PD-L1) immunohistochemical (IHC) testing in non-small-cell lung
cancer (NSCLC). This analysis is crucial for the selection of patients with advanced-stage tumors eligible for treatment with
pembrolizumab and potentially with other anti-PD-1/PD-L1 checkpoint inhibitors.This multicentric retrospective study evaluated
the reproducibility of PD-L1 testing in the Italian scenario both for closed and open platforms. In the evaluation of the well-known
gold-standard combinations (Agilent 22C3 PharmDx on Dako Autostainer versus Roche’s Ventana SP263 on BenchMark), the
results confirmed the literature data and showed complete overlapping between the twomethods. With regard to the performances
by using open platforms, the combination of 22C3 with Dako Omnis or Benchmark obtained good results basically, while the 28,8
clone seemed to be associated with worse scores.
1. Introduction
An important harmonization effort was produced by the
scientific community to standardize both the preanalytical
and interpretative phases of programmed death-ligand 1
(PD-L1) immunohistochemical (IHC) testing in non-small-
cell lung cancer (NSCLC) [1, 2]. This analysis is crucial
for the selection of patients with advanced-stage tumors
eligible for treatment with pembrolizumab and potentially
with other anti-PD-1/PD-L1 checkpoint inhibitors. Several
antibody clones (especially 22C3, 28-8, SP263, and SP142)
were evaluated and showed good reproducibility in harmo-
nization studies [3]. However, in clinical practice, further
validation efforts seem necessary since diagnostic reports
from various laboratories may be not completely overlap-
ping [4]. The Blueprint project showed that the percentage
of PD-L1 positive tumor cells was comparable for clones
22C3, 28-8, and SP263, while clone SP142 characteristically
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identified lower percentages of positive neoplastic cells [1].
Consequently, the 22C3, SP263, and 28-8 clones are usually
chosen by pathologists to test routinely cytological and
histological specimens, combining them in close and open
commercially available IHC platforms. Moreover, due to
the different technical and interpretative expertise, further
analytical variablesmay affect the final local reports [5]. In the
Italian scenario, a study confirmed a high correlation between
PD-L1 IHC expression data obtained with the 22C3 and
SP263 clones, suggesting that the two assays could be utilized
interchangeably [2]. After 1 year of PD-L1 routine testing,
the present multicentric retrospective study has aimed to
compare the results obtained by using different protocols
performed on the same tissue microarray (TMA) of a series
of NSCLC histological specimens, analyzed in different lab-
oratories and it aimed to evaluate if heterogeneous results
still persist, especially when open platforms are used. The
data were recorded in terms of interpretative/analytical error,
highlighting the current state of reproducibility in the routine
practice of PD-L1 IHC test.
2. Materials and Methods
Formalin-fixed paraffin-embedded (FFPE) histological sam-
ples from 18 lung surgical specimens with a NCSLC were ret-
rospectively selected for this study. The series included ade-
nocarcinomas and squamous cell carcinoma. The inclusion
criteria were the following: adult patients (>18 years old) who
underwent total or partial pneumonectomy in the period
between 1 December 2016 and 31 January 2018 for NSCLC; no
previous neoadjuvant chemoradiotherapy was administered.
The original samples were recovered from the archive of
the Pathology Department of University Milan Bicocca-
ASST Monza, San Gerardo Hospital, Monza. The study was
approved by the Ethical Committee of ASST Monza, under
the approval #N.1311, dated 17/07/2018. To maximize the
homogeneity in preanalytical variables, cases were selected
from a unique institution with available trackable processing
phases. For this study, fixation time was set at 24 hours
following the surgical procedure, as previously described [6].
Tissues subsequently were grossed and processed as routine
cases; a representative histological hematoxylin and eosin
(H&E) stained section of the original nodules was evaluated
by two lung-committed pathologists (FB, FP) avoiding little
fixed areas of necrosis and fibrosis and the corresponding
paraffin block was chosen for the study. For every case a PD-
L1 staining (Agilent 22C3 pharmDx on Dako Autostainer,
Dako, Glostrup, Denmark) was performed to sample TMA
cores, according to three balanced groups: score (1) Tumor
Proportion Score (TPS) negative (<1% or absence of reactiv-
ity); score (2) intermediate expressors (1-49% of tumor cells);
score (3) strong expressors (≥ 50% of tumor cells). For the
TMA construction, two separate areas were selected from the
original block (about 3mm in diameter), homogeneous for
expression patterns for PD-L1, to be punched using a 2mm-
diameter needle. The TMA layout was built using the Galileo
TMA R4.30 ISE software (Integrated Systems Engineering
Srl, Milan, Italy). The realization of the TMA blocks was
made possible by the use of the semiautomatic ISE Galileo
TMA CK 4500 arrayer (Integrated Systems Engineering).
Serial sections on positively charged slides of 1-2 micron
thickness were obtained. All the collected sections were then
kept in a thermostated oven at 60∘C overnight. Firstly, TMA
blanks were stained using two closed platforms to obtain
the gold-standard scores (Agilent 22C3 PharmDx on Dako
Autostainer and Roche’s Ventana SP263 on BenchMark with
Assay OptiView DAB IHC Detection Kit, Ventana, CA,
USA). PD-L1 staining was evaluated by two lung-committed
pathologists (FB, FP) in blind and then jointly for the final
agreement. Secondly, further TMA blanks were stained using
7 alternative protocols for PD-L1 scoring on open platforms
(Table 1). The slides were evaluated in blind from the gold-
standard results and scoring was recorded in a Microsoft
Office Excel 2007 database for the statistical analysis. All the
discordant cases were reevaluated jointly by a board team of
pathologists to identify the possible source of errors (meeting
at UNIMIB in 07/2018).
3. Results
In the first phase of the study PD-L1 using two closed
standard platforms was evaluated (Roche Ventana SP263 on
Benchmark and Dako PharmDx 22C3 on Autostainer). In
Table 2 the comparative results obtained are listed. In 15
out of 18 cases (83%) PD-L1 scoring overlapped in both
cores, using indifferently the two platforms. In 3 out 18 cases
(n. 11,12,17) the 22C3/Autostainer PD-L1 staining produced
different results in the two cores so the final grade was set
on the Ventana staining. The definitive gold-standard scores
included 6 negative cases and 7 intermediate, and 5 strong
expressors. While the conclusive results were equivalent, a
certain degree of diversity was noticed in terms of intensity.
SP263 produced stronger IHC reactivity, just easily percepti-
ble at 4x; to assess correctly 22C3 staining, a greater magnifi-
cation than 4x had to be used, in contrast to what happened
with SP263 staining, where a lowmagnification was sufficient
(Figure 1(a)). Secondly, the comparison between the gold-
standard scores and the results obtained by using 7 different
open platforms were collected in Table 3. All the discordant
cases were reevaluated by the expert board team to identify
the possible source of error.
Three possibilities were identified.
(1) Technical errors (T): exemplificative situations are
listed in Figures 1(b)–1(d).
(2) Pathologist interpretative errors (P): typical examples
are shown in Figures 2(a)–2(d).
(3) Mixed errors (M): in these cases, a combination of
low intensity due to technical reasons (compared
to gold-standard) and underestimated signal by the
pathologists produced the error.
A total of 23 out of 126 tests (18%; 4T, 15P, 4M) were affected
by the three error sources, globally; error rate (ER) of the
single centers ranged from25% (5/ 18) to 5% (1/18). Sensitivity
ranged from 69% to 92% and specificity from 33% to 100%;
the best performance was obtained by protocol n.2 using
clone 22C3 on Dako Omnis (ER=5.5%; Sn=92%; Sp=100%)
BioMed Research International 3
Table 1: Technical protocols in gold standard and open platforms of the study.
PROTOCOLS CLONE PLATFORM TITER PH Incubationprimary Ab
Incubation
linker/polymer
Gold standard 1 22C3 Autostainer PharmDx
prediluted
low
20󸀠-97∘ 30
󸀠 30󸀠/30󸀠
Gold standard 2 SP263 Ventana prediluted
(CC1) High pH
ETDA retrieval
buffer
16󸀠- 37∘ -
1 28-8 Dako Omnis 1:500 high30󸀠-97∘C 20
󸀠 10󸀠/20󸀠
2 22C3 Dako Omnis 1:20 low40󸀠 - 97∘ 40
󸀠 10󸀠/40󸀠
3 22C3 Dako Omnis 1:20 low40󸀠 - 97∘ 40
󸀠 10󸀠/40󸀠
4 22C3 Dako Omnis 1:50 low30󸀠 - 97∘ 30
󸀠 10󸀠/30󸀠
5 22C3 Dako Omnis 1:50 low30󸀠 - 97∘ 30
󸀠 10󸀠/30󸀠
6 22C3 Dako Omnis 1:20 low40󸀠 - 97∘ 40
󸀠 20󸀠/40󸀠
7 22C3 Ventana 1:40
(CC1) High pH
ETDA retrieval
buffer
32󸀠 - 36∘
12󸀠 with OptiView
DAB IHC
detection kit
Table 2: PD-L1 results of the TMA-based analysis using closed platforms.
Case 1 Case 2 Case 3 Case 4 Case 5 Case 6
22C3/Autostainer 3 1 1 2 3 3
SP263/BenchMark 3 1 1 2 3 3
FINAL SCORE 3 1 1 2 3 3
Case 12 Case 11 Case 10 Case 9 Case 8 Case 7
22C3/Autostainer 2- 3 1-2 2 1 1 2
SP263/BenchMark 3 2 2 1 1 2
FINAL SCORE 3 2 2 1 1 2
Case 13 Case 14 Case 15 Case 16 Case 17 Case 18
22C3/Autostainer 2 1 3 1 1-2 2
SP263/BenchMark 2 1 3 1 2 2
FINAL SCORE 2 1 3 1 2 2
Table 3: Comparison between the gold standard and the PD-L1 results on open platforms.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Sn Sp
1 M M T P T 69% 100%
2 P 92% 100%
3 P M 85% 100%
4 P P P P 92% 50%
5 P M P P 69% 100%
6 T T P P P 92% 33%
7 P P 85% 100%
GOLD 3 1 1 2 3 3 2 1 1 2 2 3 2 1 3 1 2 2
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(a) (b)
(c) (d)
Figure 1: (a) Case 1 (strong expressor); diversity in PD-L1 intensity using the two gold-standardmethods; by SP263 clone, the positivity was
easily evaluated at 4x; by 22C3, pathologists needed to apply a greater magnitude to confirm the reactivity in more than 50% of tumor cells.
(b) Technical error.The core was not correctly evaluated due to detachment of the TMA section (case n.10). (c) Technical error. In the picture
different levels of the same TMA-sampled core (n.18) hosted heterogeneous PD-L1 expressions. (d) Technical error. Case n.2 evaluated as
intermediate expressor using protocol n.6.The board reviewers enhanced a false positive signal in the apex of tumor cells that was not present
in the same tissue core whenever stained by other protocols. A similar technical artifact was observed also in case 3 from the same protocol.
Table 4: Correlation between open platforms and type of errors.
PROTOCOLS CLONE PLATFORMS ERRORS
1 28-8 Dako Omnis 4(2M; 1T; 1P)
2 22C3 Dako Omnis 1(P)
3 22C3 Dako Omnis 2 (1P,1M)
4 22C3 Dako Omnis 4(4P)
5 22C3 Dako Omnis 4(3P,1M)
6 22C3 Dako Omnis 5(3P,2T)
7 22C3 Ventana 2(2P)
and protocols n.3,7 (ER=11%; Sn=85%; Sp=100%) using clone
22C3 on Dako Omnis and Ventana Benchmark, respectively
(Table 4).
3.1. NegativeCases anderapy (N=6). Five out of 7 protocols
assigned correctly all the negative cases (Table 5). For 2
protocols the board pointed out in the study possible prob-
lems in terms of specificity, due to prevalent interpretative
errors. In 2 out of 6 patients PD-L1 testing was negative
Table 5: Errors in PD-L1 negative cases.
cases
protocols 2 3 8 9 14 16
1
2
3
4 P P P
5
6 T T P P
7
GOLD 1 1 1 1 1 1
independently from the platform and the center performing
the examination.
3.2. Intermediate Expressor Cases and erapy (N=7). In
the intermediate group a certain disagreement persisted;
however technical (or mixed) errors seemed to be more
relevant than in negative cases. Two out 10 errors were scored
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(a) (b)
(c) (d)
Figure 2: (a) Inappropriate evaluation of immune cells (macrophages) in crushed TMA cores may be a source of error (case 8; gold-standard
score 1, wrongly scored as 2). (b) In particular, challenging cases the average threshold of positive tumor cell cells may be wrongly assigned
(i.e., 40 versus 60%). (c) In cases (like n.17) with low-intense and focal reactivity only the evaluation at high-power field (40x) may assign
correctly as intermediate expressor the tumor, differentiating immune and neoplastic cells. (d) If a TMA core is sampled at the periphery
of the main tumor nodule, where only occasional embolic aggregates are present, they may be disregarded by a not accurate pathological
examination (case n.12).
Table 6: Errors in PD-L1 intermediate expressors.
cases
protocols 4 7 10 11 13 17 18
1 M M T T
2
3 M
4
5 M P P
6
7 P P
GOLD 2 2 2 2 2 2 2
as strong expressors instead of intermediate; in the majority
of the situations the score was underestimated (Table 6).
3.3. Strong Expressor Cases and erapy (N=5). The positive
group had a good diagnostic agreement for technical and
interpretative variables (Table 7). Case n.12 (Figure 2(d))
was particularly challenging (isolated tumor cells in normal
lung parenchyma), highlighting the importance of a high
magnification examination in absence of strong PD-L1 signal.
Table 7: Errors in PD-L1 strong expressors.
protocol 1 5 6 12 15
1 P
2 P
3 P
4 P
5 P
6 P
7
GOLD 3 3 3 3 3
4. Discussion
Immune-checkpoint inhibitors have changed the treat-
ment paradigm in locally/advanced NSCLC [7–9]. There
are four monocolonal antibodies that are currently used
in clinical practice, with some overlapping indications:
nivolumab in pretreated patients [10] as well as atezolizumab
[11], pembrolizumab that extends the possibility of using
upfront immune-checkpoint inhibitors (ICIs) [12], and more
recently durvalumab asmaintenance/consolidative treatment
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in patients with nonoperable locally advanced NSCLC who
benefit from chemoradiotherapy [13]. All these drugs have
an indication more or less linked to tumoral IHC PD-L1
expression. In particular pembrolizumab was granted in first
line setting only in tumors that express a strong PD-L1
tumor proportion score (TPS≥50%) while in further lines of
therapy a positivity of PD-L1 (≥1%) is sufficient to indicate its
employment [14]. The same situation regarding durvalumab,
after a recent post hoc analysis in which the maximum
benefit is demonstrated in PD-L1 ≥ 1%, keeps the indication
after chemoradiation in these tumors alone [13]. Nivolumab
and atezolizumab have the indication from second line
of treatment in all comers without restriction of PD-L1
tumor expression. In this scenario how the detection and
correct interpretation of PD-L1 expression on tumor cells are
crucial in order to allow the patients the best therapeutic
strategy becomes evident [15]. Beyond the technical aspects
discussed below it is important to note the intra- and
intertumoral heterogeneity of PD-L1 expression that may
affect the reproducibility of this analysis [16]. Finally, the
conservation of archived tissue samples may impact the
detection and staining degree leading to misinterpretation
of PD- L1 status [17–19]. This multicentric retrospective
study evaluated the reproducibility of PD-L1 testing in the
Italian scenario both for closed and open platforms. In the
evaluation of the well-known gold-standard combinations
(Agilent 22C3 PharmDx on Dako Autostainer versus Roche’s
Ventana SP263 on BenchMark), the results confirmed the
literature data and showed complete overlapping between
the two methods. As regards the intensity levels of the
staining, the use of the Ventana platform produced more
intense reactions in the face of a morphological more dif-
ficult distinction between the tumor cells and the immune
cells (usually alveolar macrophages, normally positive) while
the Dako platform provided fairly soft reactions but with
morphological differentiation of the most obvious cell types.
Secondly, the comparison between the gold-standard and the
PD-L1 IHC staining obtained by using 7 alternative locally
validated protocols on openplatforms reflected somepossible
sources of errors in the routine practice. The study identified
mainly two exemplificative situations: interpretative errors
(Figure 2) that affected basically false negative results and
technical ones (Figure 1). In the first group the possible
staining of the immune cells in the histological sample
may complicate the histological interpretation as the inap-
propriate application of the magnification rule that recom-
mends the use of high-power field for the scoring of mild/
focal reactivity. As shown in Table 6, in the intermediate
group the sensitivity may be affected whenever a mild or
focal staining, related to a low technical amplification or
a low antigen retrieval, is a source of false negative inter-
pretative errors. On the other hand, a low specificity is
also possible, as in protocols 4 and 6 (Table 5) due to the
difficulties of pathologists in distinguishing macrophages
from neoplastic cells in particularly challenging specimens
or avoiding false positive staining in mucus-rich tumors.
In this subgroup, the study revealed as some protocols
may frequently produce unspecific perimembranous reactiv-
ity. Every laboratory should set the proper PD-L1 protocol to
avoid this signal that is inappropriately considered as posit-
ive.
Another difficult situation was pinpointed when pathol-
ogists should decide around the threshold of 50% positive
cells, suggesting that only a careful and extensive quantitative
evaluation may avoid an underestimation in the real rou-
tine practice. Among the strong positive patients only one
(case 12) produced equivocal results, due to a particularly
challengingTMAcore that included isolated (PD-L1 positive)
tumor cells. For the technical errors, a significant proportion
of them may be related to the limitations of a TMA-based
study; the heterogeneity in the serial levels of the histological
sections may in fact exclude focal PD-L1 positive foci from
the analysis. Moreover, due to TMA intrinsic characteristics,
some cores cannot be adequately examined (Figure 1). With
regard to the performances by using open platforms, the
combination of 22C3 with Dako Omnis or Benchmark
obtained good results basically, while the 28,8 clone seemed
to be associated with worse scores.
5. Conclusions
This study was designed to stress the methodological chal-
lenges of the PD-L1 IHC testing and collected particularly
difficult cases by a preliminary histological selection of
NSCLC samples that did not reflect necessary a normal case-
mix. By these limitations, we can conclude that oncologists
should remember that the bioselection of NSCLC patients by
the PD-L1 staining has still some technical and interpretative
caveat. On the other hand, after several efforts in order
to harmonize the read-out lecture of PD-L1 status among
different antibody clones, assays, and platforms, pathologists
have now focused experiences and adequate training to give
more detailed and reproducible PD-L1 results to clinicians
[20, 21].
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